



Evolving treatment for prematurity-associated lung disease

Christopher W. Course[^], Sarah J. Kotecha[^], Sailesh Kotecha[^]

Department of Child Health, School of Medicine, Cardiff University, Cardiff, UK

Correspondence to: Sailesh Kotecha, FRCPCH, PhD. Department of Child Health, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK. Email: kotechas@cardiff.ac.uk.

Comment on: Urs RC, Evans DJ, Bradshaw TK, *et al.* Inhaled corticosteroids to improve lung function in children (aged 6-12 years) who were born very preterm (PICS1): a randomised, double-blind, placebo-controlled trial. *Lancet Child Adolesc Health* 2023;7:567-76.

Keywords: Prematurity; bronchopulmonary dysplasia (BPD); spirometry; inhaled corticosteroids; bronchodilators

Submitted Oct 12, 2023. Accepted for publication Dec 18, 2023. Published online Jan 15, 2024.

doi: 10.21037/tp-23-505

View this article at: <https://dx.doi.org/10.21037/tp-23-505>

Preterm birth remains a major world-wide health problem (1). Whilst mortality is decreasing especially at the immature gestations, it is apparent that survivors are at increased risk of life-long morbidity including from adverse respiratory outcomes. Our recently updated systematic review demonstrated that, despite advances in neonatal care over the last thirty years, lung function impairments are significant in preterm-born children, adolescents and adults including in those with and without the neonatal lung disease bronchopulmonary dysplasia [BPD, also known as chronic lung disease (CLD) of prematurity] (2). Notably, deficits in lung function are also observed in late preterm-born children who traditionally have not been considered as being at risk of long-term respiratory morbidity (3). The recent guidelines for management of BPD after discharge from the neonatal unit from both the American Thoracic Society (ATS) (4) and European Respiratory Society (ERS) (5) acknowledged the paucity of evidence to guide the long-term, post-discharge management of individuals with a neonatal history of BPD, highlighting the need for studies to assess treatment of prematurity-associated lung disease (PLD).

The Respiratory Health Outcomes in Neonates (RHINO) study has recently demonstrated that there are multiple spirometry phenotypes of PLD, including both fixed and reversible prematurity-associated obstructive lung disease (POLD), prematurity-associated preserved ratio with

impaired spirometry (pPRISm) and dysanaptic spirometry patterns, which are differentially associated with early- and current-life factors, including BPD (6). There is an increasing concern that PLD may predispose an individual to the premature development of chronic obstructive pulmonary disease (COPD) in early adulthood (7,8), with implications for quality of life and life expectancy if lung function deficits continue to track into adulthood. Whilst much research focus has concentrated on the mechanism of respiratory morbidity in those with a history of BPD (9,10), it is increasingly apparent that there is a population of preterm-born subjects who develop PLD despite not having had a diagnosis of BPD in the neonatal period (3,11), with impaired spirometry, altered respiratory mechanics and reduced gas diffusion capacity (12). Furthermore, other early life risk factors such as gestational immaturity and intrauterine growth restriction are also strongly associated with later adverse respiratory outcomes (13). Many children with PLD are often given a diagnostic label of asthma (14). However, the mechanisms underlying PLD are likely to be different to those observed in classical asthma which is often predominated by eosinophilic airway inflammation (15) and are only now beginning to be investigated (16-18). Until recently, there have been two previous studies examining inhaled therapies in the management of children with PLD, both studying participants from the pre-/peri-surfactant era (*Table 1*). Chan *et al.* performed a double-

[^] ORCID: Christopher W. Course, 0000-0002-7789-2057; Sarah J. Kotecha, 0000-0001-5640-0300; Sailesh Kotecha, 0000-0003-3535-7627.

Table 1 Summary of evidence from trials using corticosteroids inhaled in preterm-born children

Study (author, year)	Country	Inhaled therapies investigated (drug, dose, duration)	Active (n)	Placebo (n)	Results
Chan <i>et al.</i> 1993	United Kingdom	Beclomethasone dipropionate, 200 µg twice daily	15	15	Mean FEV ₁ 1.3 litres post treatment in beclomethasone group, 1.25 litres in placebo group
Pelkonen <i>et al.</i> 2001	Finland	Budesonide, 0.8 mg/m ² /day for 1 month followed by 0.4 mg/m ² /day for 3 months	18	N/A	%pred FEV ₁ 74% pre- and post-treatment (P=0.50). Significant improvement in PEFR diurnal variation (P=0.02)
RHiNO (Goulden <i>et al.</i> 2022)	United Kingdom	Fluticasone propionate, 100 µg twice daily for 12 weeks	20	14	%pred FEV ₁ increased 7.7% (95% CI: -0.3% to 15.7%, P=0.16). Mean FE _{NO} reduced from 29.8 to 15.8 ppb
		Fluticasone propionate 100 µg and Salmeterol xinafoate 50 µg, twice daily for 12 weeks	19	14	%pred FEV ₁ increased 14.1% (95% CI: 7.3% to 21.0%, P=0.002). Mean FE _{NO} reduced from 25.2 to 15.9 ppb
PICSI (Urs <i>et al.</i> 2023)	Australia	Fluticasone propionate, 125 µg twice daily for 12 weeks	87	83	0.30 (95% CI: 0.15, 0.45) improvement in FEV ₁ z-score. Reduced FEV ₁ bronchodilator response: -2.21 (95% CI: -4.68, -0.26) z-score. Mean FE _{NO} reduced from 15.2 to 10.5 ppb (P<0.05)

FEV₁, forced expiratory volume in one second; N/A, not applicable; %pred, percentage predicted; PEFR, peak expiratory flow rate; CI, confidence interval; FE_{NO}, fractional exhaled nitric oxide; ppb, parts per billion.

blind, placebo-controlled cross-over study of fifteen low birth weight children, aged eight years who were born with a mean gestational age of 30.5 weeks. All were born before the routine use of exogenous pulmonary surfactant replacement. The children received twice daily 200 µg of inhaled beclomethasone dipropionate for four weeks or placebo in a cross-over study. There was no significant effect on peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV₁) or airway hyper-responsiveness following treatment (19). In the other study occurring during introduction of exogenous surfactant treatment, Pelkonen *et al.* studied eighteen children (median gestation at birth of 28 weeks and median of age 10.1 years) who had evidence of reversibility of airway obstruction as assessed by response to short-acting β₂-agonists. These children received inhaled budesonide (0.8 mg/m²/day for 1 month followed by 0.4 mg/m²/day for 3 months) over a four-month period. No significant difference was noted for percent predicted FEV₁ (median 74% before and after treatment). However, PEFR diurnal variability improved suggesting decreased bronchial lability after treatment (20).

Whilst these two studies did not show an effect of inhaled corticosteroids on lung function in those with PLD, whether these results are applicable to the contemporary, more extremely preterm-born modern population is uncertain. The Australian conducted Preterm Inhaled Corticosteroid Intervention (PICSI) study (21) (*Table 1*)

is, therefore, a welcome addition to the literature. The group enrolled 170 children born at <32 week's gestation and aged 6–12 years old, regardless of their initial lung function status, into a randomised, double-blinded placebo-controlled trial. Children received either twice daily inhaled fluticasone propionate 125 µg or placebo for 12 weeks, undergoing spirometry, oscillometry, bronchodilator response and fractional exhaled nitric oxide (FE_{NO}) testing before and after treatment with a revised primary outcome of improvement in z-score of FEV₁ of 0.5 or greater after treatment. A third of participants had a neonatal diagnosis of BPD. Baseline lung function was comparable between the two treatment groups; 82% of participants completed the trial (83% of placebo group, 80.5% of treatment group), with drop out largely due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus pandemic. Those lost to follow-up were younger and had higher rate of BPD. The intention-to-treat analysis showed 0.30 [95% confidence interval (CI): 0.15–0.45] improvement in FEV₁ z-score in the inhaled corticosteroids group, equating to approximately 4% improvement in percent predicted FEV₁, when compared to the placebo group. Significant improvement in FEV₁/forced vital capacity (FVC) ratio and decreased FE_{NO} was also noted. 23% of the inhaled corticosteroid group improved their FEV₁ z-score by 0.5 or greater (judged as clinically significant improvement). A positive baseline response to inhaled bronchodilators,

as well as number of days of supplementary oxygen in the neonatal period, were significantly associated with treatment response.

The PICS trial demonstrated modest improvement in lung function for preterm-born children following a 12-week course of inhaled corticosteroids when compared with placebo, although an improvement of 0.3 z-score for FEV₁, equivalent of 4% percent predicted FEV₁, is unlikely to be clinically significant. However, 23% showed a more clinically beneficial improvement in FEV₁ z-score of ≥ 0.5 (equivalent to approximately 6% percent predicted FEV₁). The characteristics of these 23% was not reported but these data suggest a significant subgroup that may benefit from such treatment. It has previously been shown that FE_{NO} is not increased in PLD (15), but in the PICS study, mean FE_{NO} decreased in the inhaled corticosteroid group from 15.2 to 10.5 ppb suggesting an effect on an inflammatory pathway in the lungs of children born preterm.

Whilst the results for PICS are comparable to those reported by Chan and Pelkonen, there are suggestions that subgroups may benefit from such treatment. Atopy has not been shown to be increased in preterm-born populations who have lung disease in childhood (22). An alternative, poorly investigated intervention is the effect of long-acting bronchodilators on children who have PLD. The role of long-acting bronchodilators in PLD associated with preterm birth has been less well evaluated, with most studies assessing response to administration of single doses of short-acting β_2 -agonists (23). The RHiNO study published their results prior to the PICS study, assessing the effects of inhaled corticosteroids alone and in combination with long-acting β_2 -agonist (LABA) against placebo in preterm-born children who had significant deficits in their percent predicted FEV₁ (24). RHiNO screened over 550 children, aged 7–12 years, who were born at ≤ 34 week's gestation (together with 200 term-matched controls) from the United Kingdom. Preterm-born children with documented clinically significant lung function impairment (defined as percent predicted FEV₁ of $\leq 85\%$) were enrolled into a randomised, placebo-controlled trial assessing if 12-week treatment with twice daily inhaled corticosteroid (100 μg fluticasone propionate) alone, or in combination with a LABA (50 μg salmeterol xinafoate) improved percent predicted FEV₁ by 12% or more when compared to placebo. The study was powered to include 53 children. From 53 children who were enrolled, 48 completed the treatment protocol. Overall, compared to placebo, inhaled corticosteroids increased percentage predicted FEV₁ by

7.7% (95% CI: -0.3% , 15.7% ; $P=0.16$ when compared to placebo). Importantly, combination inhaler therapy of inhaled corticosteroids and LABA significantly improved percent predicted FEV₁ by 14.1% (95% CI: 7.3% , 21.0% ; $P=0.002$, when compared to placebo). Interestingly, participants who had not received inhaled corticosteroids previously had a significant 10.2% (95% CI: 3.8% , 16.5% ; $P=0.03$) improvement in percent predicted FEV₁ with combination inhaled therapy when compared to inhaled corticosteroids alone, and 17.2% (95% CI: 10.2% , 24.2% ; $P\leq 0.001$) improvement when compared to placebo. In this steroid naïve group, participants had similar improvement of 7.0% (95% CI: -0.9% , 15.0% ; $P=0.26$) using inhaled corticosteroids when compared to the placebo group. As with the PICS trial, there was significant decrease in FE_{NO} in both treatment groups including inhaled corticosteroids, suggesting that this may be a target for intervention in subgroups of children with PLD. Whether this represents a sub-group of preterm-born individuals with “classical” (atopic) asthma, or whether there is some overlap in the underlying biochemical mechanisms between asthma and PLD will require further evaluation.

Whilst it is well documented that preterm-born subjects generally respond well to short-acting β_2 -agonists, including those with and without a neonatal diagnosis of BPD (12,23), the Pelkonen study assessed two-week course of daily terbutaline administration. Although they did not report post-treatment lung function, they suggested improved diurnal variation of PEF (20). Monotherapy with LABAs in children with asthma has been linked with an increased risk of asthma exacerbation/hospitalisation and asthma-related deaths across several studies thus should be avoided (25). There have also been concerns in adult populations that long-term use of LABAs as monotherapy is associated with increased risk of significant cardiovascular events, including arrhythmia and myocardial infarction, with the stimulation of cardiac β_2 -adrenoceptors, increasing inotropic and chronotropic responses (26). Until safety data is established in the paediatric population, the use of LABAs alone should be avoided until safety concerns are addressed.

Due to lack of evidence, the ATS (4) and ERS (5) guidelines were largely based on expert opinion, highlighting the paucity of evidence for treatments for PLD. Both the PICS and RHiNO trials have demonstrated that the use of inhaled corticosteroids have modest improvements in spirometry after 12 weeks of treatment. Encouragingly, the RHiNO study convincingly demonstrated clinically significant improvements in spirometry above that of

inhaled corticosteroids alone when used in combination with LABA. Until additional evidence becomes available, it is reasonable to institute a trial period of combined inhaled corticosteroid and LABA therapy for 12 weeks in a preterm-born child with significant PLD, but with objective assessment of lung function before and after treatment to assess response and deciding whether to continue or stop the treatment. Future work should further identify mechanisms underlying PLD-related phenotypes, including both those with and without BPD, to identify those children most likely to benefit from current therapies, and aid development of novel treatments. Longitudinal assessment of respiratory function will be required to determine whether these short-term changes in spirometry values are maintained over the longer-term.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Translational Pediatrics*. The article has undergone external peer review.

Peer Review File: Available at <https://tp.amegroups.com/article/view/10.21037/tp-23-505/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://tp.amegroups.com/article/view/10.21037/tp-23-505/coif>). S.K. has received research grant funding from the Medical Research Council and GSK for the current work, consulted for Aspire Pharma, and received grant funding from the Moulton Foundation and Aspire Pharma outside this work. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with

the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Chawanpaiboon S, Vogel JP, Moller AB, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. *Lancet Glob Health* 2019;7:e37-46.
2. Kotecha SJ, Gibbons JTD, Course CW, et al. Geographical Differences and Temporal Improvements in Forced Expiratory Volume in 1 Second of Preterm-Born Children: A Systematic Review and Meta-analysis. *JAMA Pediatr* 2022;176:867-77.
3. Kotecha SJ, Watkins WJ, Paranjothy S, et al. Effect of late preterm birth on longitudinal lung spirometry in school age children and adolescents. *Thorax* 2012;67:54-61.
4. Cristea AI, Ren CL, Amin R, et al. Outpatient Respiratory Management of Infants, Children, and Adolescents with Post-Prematurity Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med* 2021;204:e115-33.
5. Duijts L, van Meel ER, Moschino L, et al. European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia. *Eur Respir J* 2020;55:1900788.
6. Cousins M, Hart K, Kotecha SJ, et al. Characterising airway obstructive, dysanaptic and PRISM phenotypes of prematurity-associated lung disease. *Thorax* 2023;78:895-903.
7. Gibbons JTD, Course CW, Evans EE, et al. Increasing airway obstruction through life following bronchopulmonary dysplasia: a meta-analysis. *ERJ Open Res* 2023;9:00046-2023.
8. Pulakka A, Risnes K, Metsälä J, et al. Preterm birth and asthma and COPD in adulthood: a nationwide register study from two Nordic countries. *Eur Respir J* 2023;61:2201763.
9. Um-Bergström P, Pourbazargan M, Brundin B, et al. Increased cytotoxic T-cells in the airways of adults with former bronchopulmonary dysplasia. *Eur Respir J* 2022;60:2102531.
10. Galderisi A, Calabrese F, Fortarezza F, et al. Airway Histopathology of Adolescent Survivors of Bronchopulmonary Dysplasia. *J Pediatr* 2019;211:215-8.
11. Hirata K, Nishihara M, Kimura T, et al. Longitudinal

- impairment of lung function in school-age children with extremely low birth weights. *Pediatr Pulmonol* 2017;52:779-86.
12. Hagman C, Björklund LJ, Bjermer L, et al. Lung function deficits and bronchodilator responsiveness at 12 years of age in children born very preterm compared with controls born at term. *Pediatr Pulmonol* 2023;58:3156-70.
 13. Hart K, Cousins M, Watkins WJ, et al. Association of early-life factors with prematurity-associated lung disease: prospective cohort study. *Eur Respir J* 2022;59:2101766.
 14. Crump C, Sundquist J, Sundquist K. Preterm or early term birth and long-term risk of asthma into midadulthood: a national cohort and cosibling study. *Thorax* 2023;78:653-60.
 15. Course CW, Kotecha S, Kotecha SJ. Fractional exhaled nitric oxide in preterm-born subjects: A systematic review and meta-analysis. *Pediatr Pulmonol* 2019;54:595-601.
 16. Course CW, Lewis PA, Kotecha SJ, et al. Characterizing the urinary proteome of prematurity-associated lung disease in school-aged children. *Respir Res* 2023;24:191.
 17. Course CW, Lewis PA, Kotecha SJ, et al. Modulation of pulmonary desmosomes by inhaler therapy in preterm-born children with bronchopulmonary dysplasia. *Sci Rep* 2023;13:7330.
 18. Course CW, Lewis PA, Kotecha SJ, et al. Evidence of abnormality in glutathione metabolism in the airways of preterm born children with a history of bronchopulmonary dysplasia. *Sci Rep* 2023;13:19465.
 19. Chan KN, Silverman M. Increased airway responsiveness in children of low birth weight at school age: effect of topical corticosteroids. *Arch Dis Child* 1993;69:120-4.
 20. Pelkonen AS, Hakulinen AL, Hallman M, et al. Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm. *Respir Med* 2001;95:565-70.
 21. Urs RC, Evans DJ, Bradshaw TK, et al. Inhaled corticosteroids to improve lung function in children (aged 6-12 years) who were born very preterm (PICSJ): a randomised, double-blind, placebo-controlled trial. *Lancet Child Adolesc Health* 2023;7:567-76.
 22. Edwards MO, Kotecha SJ, Lowe J, et al. Management of Prematurity-Associated Wheeze and Its Association with Atopy. *PLoS One* 2016;11:e0155695.
 23. Kotecha SJ, Edwards MO, Watkins WJ, et al. Effect of bronchodilators on forced expiratory volume in 1 s in preterm-born participants aged 5 and over: a systematic review. *Neonatology* 2015;107:231-40.
 24. Goulden N, Cousins M, Hart K, et al. Inhaled Corticosteroids Alone and in Combination With Long-Acting β_2 Receptor Agonists to Treat Reduced Lung Function in Preterm-Born Children: A Randomized Clinical Trial. *JAMA Pediatr* 2022;176:133-41.
 25. Xia Y, Kelton CM, Xue L, et al. Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma. *Ther Adv Drug Saf* 2013;4:254-63.
 26. Wang MT, Lai JH, Tsai CL, et al. Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease. *J Food Drug Anal* 2019;27:657-70.

Cite this article as: Course CW, Kotecha SJ, Kotecha S. Evolving treatment for prematurity-associated lung disease. *Transl Pediatr* 2024;13(1):1-5. doi: 10.21037/tp-23-505